Compare Affirm Holdings Inc (AFRM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Affirm Holdings Inc vs TG Therapeutics Inc — how do they compare? Affirm Holdings Inc trades at $74.01 (market cap $25.69B), while TG Therapeutics Inc trades at $49.58 (market cap $7.64B). The key difference: Affirm Holdings Inc is far larger — about 3.4× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| AFRM | TGTX | |
|---|---|---|
Market Cap | $25.69B | $7.64B |
Sector | Financials | Health |
52-Week High | $92.18 | $59.06 |
52-Week Low | $42.53 | $26.94 |
Enterprise Value | $32.30B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFRM trades at $74.13, down 1.87% in the last session, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported strong revenue growth, reaching $3.22 billion in 2025, and achieved profitability with a net income of $52.19 million, marking a significant turnaround from prior losses. Recent earnings beats and a consensus analyst price target of $95.75 suggest optimism, though high valuation ratios like a P/E of 69.73 indicate premium pricing.
The outlook for AFRM is positive due to accelerating revenue growth and improving cash flow, but risks include sensitivity to interest rate changes and competitive pressures in fintech. Investors should weigh the high valuation against the potential for sustained earnings expansion, with institutional sentiment leaning bullish based on analyst coverage.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
